T-3011 is under clinical development by Immvira and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase I drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how T-3011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
T-3011 overview
T-3011 is under development for the treatment of advanced malignancy, solid tumors such as metastatic melanoma, advanced melanoma, hepatocellular carcinoma, colorectal cancer, malignant ascites, ovarian cancer, non-muscle invasive bladder cancer (NMIBC), lung cancer, liver cancer, lymphoma, malignant pleural mesothelioma, breast cancer, sarcomas, lung cancer, head and neck squamous-cell carcinoma, cutaneous squamous cell carcinoma (cSCC), esophageal cancer and non-small cell lung cancer, pancreatic cancer, colon cancer, endometrial cancer, malignant glioma, myalgic encephalomyelitis (ME), bladder cancer and ovarian cancer. The drug candidate is a re-targeted next generation herpes simplex virus (oncolytic virus) encoding PD-1 antibody and interleukin 12 (IL12) gene. It is administered through intratumoral, intraperitoneal and intravenous drip route.
Immvira overview
Immvira is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, which not only improves the replicating ability of the virus but also further improves the oncolytic activity of the virus and promotes the immune response. The company is headquartered in Shenzhen, Guangdong, China.
For a complete picture of T-3011’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
